ReviewJournal of scleroderma and related disorders2019

Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.

Lutz Wollin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.